Time	Topic	Speaker	Moderator	
08:15-08:20		Ling-Ming Tseng Shih-Chung Chen		
08:20-08:30	Opening Remarks			
	Progress and Challenge			
08:30-09:10	Lessons learned in the treatment of breast cancer over the past five decades	Gabriel Hortobagyi	Ling-Ming Tseng	
	Targeted Therapy 1			
09:10-09:15	Case presentation, and vote	Jiun-l Lai		
09:15-09:45	Use of Tyrosine Kinase Inhibitors in the treatment of HER2-positive breast cancer	Adam Brufsky	Hwei-Chung Wang	
09:45-10:15	PI3K inhibitor in HR+ HER2- advanced breast cancer	Ingrid Mayer	Tsu-Yi Chao	
10:15-10:40	Panel discussion	Adam Brufsky / Ingrid Mayer/Wen-Ling Kuo Chih-Chiang Hung /Ying-Wen Su		
10:40-11:00	Coffee Break			
11:00-11:30	PARP inhibitors and immune checkpoint therapy on breast cancer	Mien-Chie Hung	King-Jen Chang Hsien-Tang Yeh	
11:30-12:00	Ethnic difference in breast cancer treatment	Hiroji Iwata	Shyr-Ming Sheen-Cher	
12:00-12:30	Cracking the genetic codes to unlock treatment options: a lesson from CGP on real-world cases	Chien-Feng Li	Fang-Ming Chen	
	I/O and Chemotherapy			
12:30-13:10	Luncheon Symposium Combination strategies of checkpoint immunotherapy and	Ming-Shen Dai	Hsien-Kun Chang	
	chemotherapy in metastatic triple negative breast cancer			
13:10-13:20	Break			
13:20-13:25	Case presentation, and vote	Yi-Fang Tsai		
13:25-13:55	Raise the bar higher: evolving treatment landscape in neoadjuvant TNBC with immunotherapy	Ming-Shen Dai	Jyh-Cherng Yu	
13:55-14:25	Future roles of IO in breast cancer treatment- neoadjuvant/adjuvant/combination	Mei-Ching Liu	Ming-Feng Hou	
14:25-14:55	The transforming advancement in mBC treatment in 2020	Peter Schmid	Yen-Shen Lu	
14:55-15:15	Panel discussion	Ming-Shen Dai / Mei-Ching Liu Peter Schmid / Wen-Hung Kuo Liang-Chih Liu / Dwan-Ying Chang		
15:15-15:35	Coffee Break			
	Targeted Therapy II			
15:35-15:40	Case presentation, and vote	Chien-Ting Liu		
15:40-16:10	HER2 EBC treatment overview	Luca Gianni	Chiun-Sheng Huang	
16:10-16:40	Bringing biosimilars to life: clinical experience sharing	Marc Thill	Chien-Liang Liu	
16:40-17:10	Two decades after BRCA discovery: hereditary breast cancer, homologous recombination deficiency and PARP inhibitor	Po-Han Lin	Ching-Hung Lin	
17:10-17:40	DDR science and early BRCA testing	Shani Paluch Shimon	Shin-Cheh Chen	
17:40-18:00	Panel discussion	Luca Gianni/ Marc Thill/ Po-Han Lin Shani Paluch Shimon / Yuan-Ching Chang Huan-Ming Hsu / Wei-Pang Chung		

Time	Topic	Speaker	Moderator	
08:00-08:50	Abstract oral presentation	Ling-Ming Tseng		
08:50-09:00	Molecular profiling of Taiwanese Breast Cancers	Chi-Cheng Huang	136118	
09:00-09:20	Unique characteristics of breast cancer in East Asia	Yen-Shen Lu	Ming-Feng Hou	
09:20-09:35	致詞/永齡華人抗癌聯盟簡介/頒感謝狀		l ing Tseng	
03.20 03.33	Luminal ABC	Ling Wi	ing iseng	
09:35-09:40	Case presentation, and vote	Lo Chiao		
09:40-10:10	Treatment choice in post CDK4/6 inhibitor era	Naoto Ueno	Chiun-Sheng Huang	
10:10-10:40	CDK4/6 inhibitor and immune modulation	Shom Goel	Ming-Hsin Yeh	
10:40-11:00	Coffee Brea	1	Willig-HSIII Tell	
10:40-11:00	Emerging evidence on the uniqueness of Asian	T		
11:00-11:30	premenopausal breast cancer	Ching-Hung Lin	TBD	
11:30-12:00	Envision a longer future: uncover the new era of endocrine treatments in HR+ HER2- metastatic breast cancer	Ta-Chung Chao	Kun-Ming Rau	
12:00-12:20	Panel discussion	Naoto Ueno / Shom Goel / Ching-Hung Lin Ta-Chung Chao / Ming-Yang Wang Shih-Che Shen / Chun-Yu Liu		
12:20-13:00	Luncheon Symposium New developments in chemotherapy-based treatment for early breast cancer	Chin-Sheng Hung	Dah-Cherng Yeh	
13:00-13:20	Break			
	Special Lecture			
13:20-13:50	Artificial intelligence in breast cancer medicine	Kung-Hao Liang	Fiona Tsui-Fen Cheng Chao-Ming Hung	
13:50-14:20	Clinical breast cancer practice during COVID-19 pandemic	Hsiu-Hsi Chen	King-Jen Chang Chen-Hsiang Chang	
14:20-14:50	COVID19: ensuring the quality, resiliency, and continuity of breast cancer care during a pandemic	Chieh-Han Chuang	Fang-Ming Chen Chin-Hua Tsai	
14:50-15:10	Coffee Break			
	Local Regional Therapy			
15:10-15:30	Lessons learned from nipple-sparing mastectomy with oncologic outcomes	Shin-Cheh Chen	Dar-Ren Chen	
15:30-15:50	Locoregional management after NAC	Jeong Eon Lee	Shih-Hsin Tu	
15:50-16:10	Multidisciplinary management of locoregional recurrence	Jyh-Cherng Yu	Shou-Tung Chen	
16:10-16:30	Whole brain radiotherapy for breast cancer patients with brain metastases: The role of hippocampal avoidance	Wen-Chi Yang	Ling-Ming Tseng	
16:30-16:50	Panel discussion	Shin-Cheh Chen / Jeong Eon Lee Jyh-Cherng Yu / Wen-Chi Yang Frank Fu Ou-Yang / Kuo-Ting Lee / Kuo-Hsiu Lia		
16:50-17:00	Award Ceremony & Closing	Ling-Ming Tseng		